Insight Molecular Diagnostics Inc. · NASDAQ:IMDX
Insight Molecular Diagnostics — OncoCyte — Investor Presentation (January 2020)
14 slides from Insight Molecular Diagnostics's investor presentation, Jan 10, 2020
Slide 1: OncoCyte - Where Tomorrow Lives
a ONCOCYTE WHERE TOMORROW LIVES.
Slide 2: We are building a global oncology content company
We are building a global oncology content company with an expanding portfolio of high value molecular tests, that help physicians and patients make informed care decisions to improve outcomes, reduce overall cost of care and drive significant returns for our shareholders.
Slide 3: Addressing Unmet Needs Across The Lung Cancer Continuum
Addressing Unmet Needs Across The Lung Cancer Continuum Is the treatment effective? Js there a suspicion of Should | biopsy the ‘Should | give adjuvant Should | give an Should give Targeted ie Geet apices haptoaaee Gena immune Wreapy? therapy? Ithe cancer coming Therapy Selection Therapy Selection T
Slide 4: Opportunity Selection and Lung Opportunity
Opportunity Selection and Lung Opportunity High degree of scientific Lung Play Advantages confidence Builds toward OCX as one-stop shop for lung cancer diagnostics Serve clinical oncology (focus on Economy of scale — leverages OCX sales team, commercial lung) infrastructure Reimbursable content, or
Slide 5: Insight Acquisition Establishes Oncocyte as a Leader in Lung Cancer Diagnostics
in Insight Acquisition Establishes Oncocyte as a Leader in Lung a Cancer Diagnostics INSIGHT DETERMAD, ao DETERMAS” | rt Likely POUPD-LI Responder Treatment Test Iermedite! Ad Acar or Intereiate im HghRsk Chemotherapy Advanced Concer (+3 Risk Nodules Confirmatory J Attemative Treatment ome] tr | Str
Slide 6: Insight Genetics
Insight Genetics Innovating novel precision medicine solutions and delivering unparalleled pharma and clinical testing services ONCOCYTE Full-service precision medicine company founded in 2007 Novel proprietary Immuno-oncology assay. Outperforms current biomarkers PD-L1/TMB in identifying responders
Slide 7: Significant Unmet Need for Better Predictive Markers for Immune Oncology Drugs
a : Significant Unmet Need for Better Predictive for Immune Oncology Drugs POLL Expression) + 750K cancer pts eligible for immune therapy, only 12.5% patients respond to treatment (JAMA 2019) + Potential for unpredictable and fatal toxicity and high [scorns hil be treatment cost (>$250K) makes this
Slide 8: IM Score
IM Score Insight 1O Panel — Performance in NSCLC (SITC 2019) Average PD-L1 Staining ‘Average IM Score for Objective Response ferOulscive Recneriae Average TMB for Objective Response “] Pvalue (spearman) <0.001. I me P-value 0.20 6 478 ° . a P-value 0.999 & 0.33' « €- 8 g ©] p<o.001 g a5 447 % ge4 aR
Slide 9: Insight Genetics Proprietary IO Product Pipeline Seeks to Address this Unmet Need
Insight Genetics Proprietary |O Product Pipeline Seeks to Address this Unmet Need Product Stage of Development iti jicatie Future Indications IM , . . (30 genes; qPCR) Final Validation TNBC; NSCLC 10 Diseases ARTEMIS (MD Anderson) TNBC PARPi z (101 genes; NGS) Initial Validation TNBC Ovarian ARTEMIS
Slide 10: Insight TNBC Assay — Performance
Insight TNBC Assay — Performance Clinical Evidence + BLA Patients respond favorably to taxane treatment; J Masuda 201: 3 eee and IG's own + BL2 patients respond poorly ing 2016 es 9, + BLi patients may respond to PARP inhibitors Severson 2015 * BL predicts favorable response to taxanes + _M patients
Slide 11: Full Service for Pharma & Biotech Partners
Full Service for Pharma & Biotech Partners Uniquely Positioned to Provide Solutions from Innovation and Early Development through Clinical Application INSIGHT Bomereer + Insight has development expertise across =e Content the spectrum of molecular platforms and és technologies (singleplex, multiplex
Slide 12: Insight Genetics Regulatory and Quality Approvals Allow For Pharma and BioTech Engagement
Insight Genetics Regulatory and Quality Approvals Allow ’ For Pharma and BioTech Engagement Current Audits and Certifications: Insight Genetics, Inc. + All assays designed according to the Clinical and Laboratory Standards Institute guidelines. + ISO 9001 2015 Certification (current; established 201
Slide 13: Insight Genetics Investment Summary
#5 Insight Genetics Investment Summary + Full-service precision oncology company — novel biomarker development, assay dev and validation, clinical trials, regulatory submission + Proprietary Immune-oncology gene expression test targeting a $2B clinical and $400M (3000 active global clinical trials)
Slide 14: Contact Us
BK CONTACT US Oncocyte.com